Valuation : NetraMark Holdings Inc.

Market Cap 64.35M 46.38M 39.96M 37.84M 34.3M 4.43B 64.67M 449M 173M 2.25B 174M 170M 7.12B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 64.35M 46.38M 39.96M 37.84M 34.3M 4.43B 64.67M 449M 173M 2.25B 174M 170M 7.12B EV / Sales 2026 *
160x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
Sep. 10 NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models CI
Sep. 01 Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors CI
Aug. 14 NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
Jul. 09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
Jul. 09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
Jun. 29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
Jun. 29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
May. 14 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
May. 07 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
May. 04 NetraMark Holdings Inc. Announces Executive Changes CI
Apr. 22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
Apr. 20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
Apr. 09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
1 day-2.86%
1 week+4.62%
Current month+6.25%
1 month+3.03%
3 months-16.05%
6 months-33.98%
Current year-38.18%
1 week 0.67
Extreme 0.67
0.7
1 month 0.6
Extreme 0.6
0.75
Current year 0.59
Extreme 0.59
1.28
1 year 0.59
Extreme 0.59
1.65
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
1.97
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 2022-02-16
President - 2022-07-03
Director of Finance/CFO 57 2022-07-17
Director TitleAgeSince
Chairman 40 2025-06-08
Director/Board Member - -
Director/Board Member - 2022-06-15
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Other

Director

0 0%
9/1/26 Other

Director

0 0%
8/25/26 Buy

Director

30,000 0.0323%
Change 5-day change 1-year change 3-year change Capi.($)
-2.86%+4.62%-54.36%+189.36% 46.38M
+0.65%-0.81%-2.80%+47.48% 3,680B
+0.83%-4.07%-2.45%+971.99% 402B
+1.55%-1.14%-15.75%+20.01% 79.69B
-0.23%+3.89%+62.06%+126.93% 79.43B
+0.05%+0.90%-6.60%-14.88% 76.15B
-1.35%-5.22%-45.81%+172.20% 65.07B
+0.07%-5.21%+2.76%-13.97% 45.49B
-0.69%+0.36%-12.50%+49.26% 40.29B
-1.64%-2.42%+122.17%+252.04% 34.92B
Average -0.36%-0.91%+4.67%+180.04% 450.33B
Weighted average by Cap. +0.59%-1.11%-1.60%+132.63%

Financials

2026 *2027 *
Net sales 401K 289K 249K 236K 214K 27.61M 403K 2.8M 1.08M 14.05M 1.09M 1.06M 44.39M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
26-09-11 CA$0.6800 -2.86% 30,120
26-09-10 CA$0.7000 0.00% 19,493
26-09-09 CA$0.7000 0.00% 9,675
26-09-08 CA$0.7000 +7.69% 64,550

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!